Bayer teams up with biotech firm Arvinas in deal worth up to $750 million [Reuters (UK)]
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: Reuters
Bayer teams up with biotech firm Arvinas in deal worth up to $750 million - Reuters 2 Min Read FRANKFURT (Reuters) - German drugmaker Bayer has signed an alliance with Arvinas Inc to gain access to the U.S. biotech firm’s experimental protein drugs and crop protection technology in a deal worth up to $750 million. Under the pact, Arvinas will receive an upfront payment, pharmaceutical research and development (R&D) support and a direct equity investment of more than $60 million. In addition, milestone payments linked to development achievements and commercial royalties could add up to slightly more $685 million, Bayer said in a statement on Tuesday. Bayer, which is cutting jobs and revamping its drug development activities, has said it will
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual MeetingGlobeNewswire
- Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $15.00 to $12.00. They now have a "neutral" rating on the stock.MarketBeat
- Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple [Yahoo! Finance]Yahoo! Finance
ARVN
Earnings
- 2/11/25 - Beat
ARVN
Sec Filings
- 4/17/25 - Form SCHEDULE
- 4/4/25 - Form 8-K
- 3/19/25 - Form 4
- ARVN's page on the SEC website